GLF
SKYE icon

Groupe la Francaise’s Skye Bioscience SKYE Stock Holding History

Groupe la Francaise’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-14
Closed -$46 – 801
2025
Q3 		$46 Buy
+14
New +$53 ﹤0.01% 769

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Groupe la Francaise's SKYE Position: Q4 2025 in Review

Groupe la Francaise sold out of Skye Bioscience (SKYE) in Q4 2025, closing a stake of 14 shares — an estimated $46 sold.

Groupe la Francaise first reported a position in SKYE in Q3 2025 and held it in 1 quarter. The position peaked at $46 in Q3 2025. 50 funds tracked by Wall St. Rank hold SKYE as of Q4 2025.

  • Groupe la Francaise reported no remaining Skye Bioscience position as of Q4 2025 after selling out during the quarter.
  • Groupe la Francaise sold 14 Skye Bioscience shares in Q4 2025, an estimated $46.
  • Groupe la Francaise first reported a position in Skye Bioscience in Q3 2025 and held it in 1 quarter.
  • Groupe la Francaise's Skye Bioscience position peaked at $46 in Q3 2025.
  • 50 funds tracked by Wall St. Rank held Skye Bioscience as of Q4 2025.

Based on Groupe la Francaise's 13F filing for Q4 2025, filed 12 Feb 2026.